Ligesom med andre koagulationsfaktor VIII- produkter skal patienterne monitoreres med hensyn til udviklingen af inhibitorer, der skal titreres i Bethesda- enheder (BE) under anvendelse af Nijmegen- modifikationen af Bethesda- analysen.
As with all coagulation factor VIII products, patients are to be monitored for the development of inhibitors that are to be titrated in Bethesda Units (BUs) using the Nijmegen modification of the Bethesda assay.